Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by theguru1on Oct 29, 2009 1:10pm

250 Views

Post# 16435641

RE: Friday the 13th

Friday the 13th maybe the best day to release there scarry numbers. I think 50 million for year end revenue has to be too low (53 mil) but 9 mil. for the quarter may be close (I'm hoping for 10). Still think if revenue numbers were lower then 9 mill. they would have warned. (Atleast I hope)

Bullboard Posts

BlackBerry’s cost-cutting yields Q1 2024 savings